vironexis
vironexis.com
Actively hiring
Biotechnology
Health Care
Cell & Gene Therapy
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Moonshots Capital
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
Moonshots Capital Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
计时中 Home About Pipeline Science Overview PDV LNP News Careers Leadership Zongli ZHENG Co-Founder, Chairman MORE ▶ Tian ZHU Co-Founder，CEO…
Transforming disease treatment through cell and gene therapy. Join us at BlueRock to discover our cutting-edge science & clinical programs.
Q-Immune provides cutting-edge real-time protein network analysis for CAR-T cells, enabling accurate efficacy prediction, optimized CAR-T…
At cellvie, we are pioneering Therapeutic Mitochondria Transplantation, a novel treatment approach aimed at the cellular energy metabolism.
Discover GC Therapeutics, a pioneer in scalable, cutting-edge cell therapies designed to revolutionize treatment across a broad range of…
Early-stage biotech in immunotherapy with an international team of experts and founders aiming to develop and deliver personalized…
News
Vironexis Announces Complete and Durable Responses in Relapsed/Refractory ALL Patients Treated with VNX-101
In the ongoing SENTRY-CD19 trial, all three anti-AAV antibody-naïve patients with relapsed/refractory acute lymphoblastic leukemia (ALL) have achieved MRD-negative complete responses following a single administration of VNX-101 Responses have demonstrated
Read more
Report
Vironexis Announces Complete and Durable Responses in Relapsed/Refractory ALL Patients Treated with VNX-101
In the ongoing SENTRY-CD19 trial, all three anti-AAV antibody-naïve patients with relapsed/refractory acute lymphoblastic leukemia (ALL) have achi...
Read more
Report
Vironexis Announces Complete and Durable Responses in Relapsed/Refractory ALL Patients Treated with VNX-101
In the ongoing SENTRY-CD19 trial, all three anti-AAV antibody-naïve patients with relapsed/refractory acute lymphoblastic leukemia (ALL) have achieved MRD-negative complete responses following a single administration of VNX-101 Responses have demonstrated
Read more
Report
Vironexis Biotherapeutics Launches with FDA Clearance of IND Application for First-Ever Clinical Trial of an AAV-delivered Cancer Immunotherapy
Vironexis's off-the-shelf, single-dose gene therapies aim to deliver cancer treatments that are safer, more effective and long-lasting, and more easily manufactured and administeredLeveraging its TransJoin platform, Vironexis has built a pipeline of more
Read more
Report
Vironexis Biotherapeutics Launches with FDA Clearance of IND Application for First-Ever Clinical Trial of an AAV-delivered Cancer Immunotherapy
Vironexis's off-the-shelf, single-dose gene therapies aim to deliver cancer treatments that are safer, more effective and long-lasting, and more easily manufactured and administered Leveraging its TransJoin platform, Vironexis has built a pipeline of more
Read more
Report